Ionis Pharmaceuticals
IONS
Market cap $6.07B

38.49 USD

-0.67

1.71%

At close Oct 17, 4:00 PM EDT

After hours

38.49

+0.00

0.00%

1 day

-1.71%

5 days

1.08%

1 month

-7.28%

3 months

-19.75%

6 months

-5.92%

Year to date

-27.20%

1 year

-20.66%

5 years

-31.92%

About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Employees: 927

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 12 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

250% more call options, than puts

Call options by funds: $117M | Put options by funds: $33.5M

20% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]

11% more capital invested

Capital invested by funds: $6.18B [Q1] → $6.84B (+$664M) [Q2]

0.69% more ownership

Funds ownership: 97.64% [Q1] → 98.33% (+0.69%) [Q2]

0% more funds holding

Funds holding: 352 [Q1] → 352 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 53

6% less repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 129

See Fund Rankings

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$37

4%

downside

Avg. target

$60

55%

upside

High target

$70

82%

upside

12 analyst ratings

8 positive

67%

3 neutral

25%

1 negative

8%

Guggenheim Debjit Chattopadhyay 70% 1-year accuracy 7 / 10 met price target	69%upside $65	Buy Maintained	9 Oct 2024
RBC Capital Luca Issi 38% 1-year accuracy 18 / 48 met price target	82%upside $70	Outperform Reiterated	26 Sept 2024
JP Morgan Jessica Fye 73% 1-year accuracy 24 / 33 met price target	43%upside $55	Neutral Maintained	26 Aug 2024
Guggenheim Debjit Chattopadhyay 70% 1-year accuracy 7 / 10 met price target	82%upside $70	Buy Maintained	2 Aug 2024
Goldman Sachs Salveen Richter 56% 1-year accuracy 10 / 18 met price target	4%downside $37	Sell Maintained	2 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about IONS published over the past 30 days

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

– Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif. , Oct. 3, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE).

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Zacks Investment Research

IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease.

IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

Zilganersen is the first investigational medicine in clinical development for adults and children living with Alexander disease, an ultra-rare neurological condition CARLSBAD, Calif. , Oct. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted zilganersen Fast Track designation for the treatment of children and adults with an ultra-rare, progressive and ultimately fatal neurological disorder known as Alexander disease (AxD).

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

Zacks Investment Research

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering

IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Tuesday.

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Ionis announces pricing of $500.3 million public offering

CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock.

Ionis announces pricing of $500.3 million public offering

Ionis announces proposed public offering of common stock

CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock.

Ionis announces proposed public offering of common stock

Ionis to present at upcoming investor conferences

CARLSBAD, Calif. , Aug. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events.

Ionis to present at upcoming investor conferences

Zacks Investment Research

Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?

Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.

Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Ionis Pharmaceuticals specializes in RNA-targeted therapies for neurological and cardiometabolic diseases using antisense DNA technology. The company has a robust pipeline with over 40 drug candidates, developed in partnership with major pharmaceutical companies and in-house. In 2024, Ionis launched Wainua for ATTRv-PN and Qalsody for SOD1-ALS, marking significant milestones in its product portfolio.

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

See News Rankings

Charts implemented using Lightweight Charts™